← back to search

Per Ljungman

European Society for Blood and Marrow Transplantation · SE
Area of research
Hematology · Epidemiology
Research interest
Research interests include Hematopoietic Stem Cell Transplantation, Cytomegalovirus and herpesvirus research, Acute Myeloid Leukemia Research, and Polyomavirus and related diseases.
h-index
110
citations
49,927
works
787
NIH funding
primary concept
email

Recent publications

Community-acquired respiratory virus infections in patients with haematological malignancies or undergoing haematopoietic cell transplantation: updated recommendations from the 10th European Conference on Infections in Leukaemia.
2026cited by 2position: contributordoi
Vaccination should not be forgotten in patients receiving immunoglobulin replacement therapy.
2026cited by 1position: contributordoi
Changing scenario in prevention and management of CMV infections in pediatric hematopoietic stem cell transplant patients.
2026cited by 0position: contributordoi
Impact of donor and recipient EBV serostatus on transplant outcomes in patients with acute leukemia after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide: Infectious Diseases Working Party EBMT retrospective study.
2026cited by 0position: contributordoi
Length of SARS-CoV-2 shedding in HCT recipients: an Infectious Disease Working Party of EBMT study.
2026cited by 0position: contributordoi
Symptom-guided approach to central nervous system complications in allogeneic hematopoietic cell transplant recipients: Best practice recommendations from the EBMT Practice Harmonisation and Guidelines committee.
2026cited by 0position: contributordoi
Central nervous system complications after allogeneic haematopoietic cell transplantation: best practice recommendations from the EBMT practice harmonisation and guidelines committee on epidemiology, outcome and neuroimaging.
2026cited by 0position: contributordoi
Overcoming barriers to adult immunization in Europe: A decalogue for policy action by the Adult Immunization Board
Health Policy and Technology 2026cited by 0position: contributordoi
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder — recommendations from ECTRIMS and the EBMT
Nature Reviews Neurology 2025cited by 42position: middledoi
Refractory and Resistant Herpes Simplex Virus Mucocutaneous Infections in Immunocompromised Patients: Literature Review and Proposed Definitions for Use in Clinical Trials.
2025cited by 7position: contributordoi
Post-pandemic recommendations for the management of COVID-19 in patients with haematological malignancies or undergoing cellular therapy, from the European Conference on Infections in Leukaemia (ECIL-10).
2025cited by 6position: contributordoi
An ASTCT, CIBMTR, EBMT, and APBMT Consensus Statement Defining Response Criteria for Hematopoietic Cell Transplantation Associated Thrombotic Microangiopathy (TA-TMA) Directed Therapy
Transplantation and Cellular Therapy 2025cited by 6position: contributordoi
Pneumonia definition in allogeneic hematopoietic cell transplant recipients: Update and challenges in 2024. Recommendations from the EBMT Infectious Diseases Working Party and Practice Harmonization and Guidelines committee
Current Research in Translational Medicine 2025cited by 2position: middledoi
Author's Reply to the correspondence: ECIL-10 guidelines for COVID-19 should take convalescent plasma into proper consideration by Focosi et al.
2025cited by 1position: contributordoi
Advancing the Integration of ‘Basic/Fundamental’ and Translational Cellular and Gene Therapy Science within the EBMT: Accelerating the Pathway to Progress
Bone Marrow Transplantation 2025cited by 1position: middledoi
The Stockholm early detection of cancer study (STEADY-CAN): rationale, design, data collection, and baseline characteristics for 2.7 million participants.
2025cited by 0position: contributordoi
Advancing the Integration of 'Basic/Fundamental' and Translational Cellular and Gene Therapy Science within the EBMT: Accelerating the Pathway to Progress.
2025cited by 0position: contributordoi
Clinical characteristic and outcome of HHV-6 encephalitis after allogeneic hematopoietic cell transplantation: A study of Infectious Disease Working Party of EBMT.
2025cited by 0position: contributordoi
Clinical characteristic and outcome of HHV-6 encephalitis after allogeneic hematopoietic cell transplantation: A retrospective study of Infectious Disease Working Party of EBMT
2025cited by 0position: contributordoi
Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum
Clinical Infectious Diseases 2024cited by 137position: firstdoi
Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum.
2024cited by 89position: contributordoi
Vaccination of Adults With Cancer: ASCO Guideline.
2024cited by 60position: contributordoi
Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT
Bone Marrow Transplantation 2024cited by 58position: middledoi
Memory T cells effectively recognize the SARS-CoV-2 hypermutated BA.2.86 variant
Cell Host & Microbe 2024cited by 37position: middledoi
Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT.
2024cited by 32position: contributordoi
Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation
Journal of Clinical Oncology 2024cited by 29position: middledoi
Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation.
2024cited by 24position: contributordoi
Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXID
EBioMedicine 2024cited by 14position: middledoi
Identification and surveillance of rare relapse-initiating stem cells during complete remission after transplantation.
2024cited by 13position: contributordoi
Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy.
2024cited by 12position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 68 papers (2019–2026)Jan Styczyński · Nicolaus Copernicus University31 papers (2014–2026)Rafael de la Camara · European Society for Blood and Marrow Transplantation23 papers (2019–2026)Nicolaus Kröger · Universität Ulm20 papers (2016–2026) · 19 papers (2020–2026)Rafael de la Cámara · European Society for Blood and Marrow Transplantation16 papers (2013–2024)Simone Cesaro · Azienda Ospedaliera Universitaria Integrata Verona16 papers (2020–2026)Diana Averbuch · Hadassah Academic College15 papers (2021–2026)Malgorzata Mikulska · University of Genoa14 papers (2021–2026)Catherine Cordonnier · Université Paris-Est Créteil13 papers (2012–2023)Jakob Passweg · Centre Hospitalier Universitaire de Nantes12 papers (2016–2022)Małgorzata Mikulska · Istituto Nazionale di Fisica Nucleare, Sezione di Genova12 papers (2019–2025)Stephan Mielke · Karolinska University Hospital12 papers (2019–2024)Hans H. Hirsch · Vir Biotechnology (Switzerland)11 papers (2012–2026)Simone Cesaro · Azienda Ospedaliera Universitaria Integrata Verona10 papers (2014–2025)John Snowden · Guy's Hospital9 papers (2020–2024)Silvia Montoto · Università Campus Bio-Medico9 papers (2019–2021)Rafael F. Duarte · Hospital Universitario Puerta de Hierro Majadahonda9 papers (2017–2021)Johan Maertens · Ospedale Policlinico San Martino8 papers (2015–2023) · 8 papers (2021–2026)